Pharmacovigilance [Pharmacovigilance update]

Fiche du document

Auteurs
Date

13 janvier 2021

Types de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2021.17.720-21.0080

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33443836

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A6BCD3D8DD4E2

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/

Mots-clés 0

Adenosine Monophosphate/analogs & derivatives; Adenosine Monophosphate/therapeutic use; Alanine/analogs & derivatives; Alanine/therapeutic use; COVID-19/drug therapy; Cleft Lip/prevention & control; Contraindications, Drug; Cytokine Release Syndrome/virology; Female; Fingolimod Hydrochloride/adverse effects; Humans; Hydroxychloroquine/adverse effects; Leiomyoma/drug therapy; Norpregnadienes/therapeutic use; Pharmacokinetics; Pharmacovigilance; Pregnancy; Ranitidine/adverse effects; Safety-Based Drug Withdrawals; Skin Neoplasms/chemically induced

Sujets proches En

Therapy Treatments for diseases Medical treatment Therapy Treatment of diseases Integument (Skin) Cutis Gestation Kinetics, Drugs Drug kinetics Drugs--Pharmacokinetics Drugs--Kinetics

Citer ce document

P. Ekobena et al., « Pharmacovigilance [Pharmacovigilance update] », Serveur académique Lausannois, ID : 10.53738/REVMED.2021.17.720-21.0080

Métriques

Partage / Export

Résumé 0

The main pharmacovigilance updates in 2020 are reviewed. Remdesivir in COVID-19: relatively safe but turns out to be less effective than expected. Hydroxychloroquine in COVID-19 : lack of efficacy and risk of arrhythmias. Cytokines storm in COVID-19: may impact pharmacokinetics. VEGF inhibitors: risk of aneurysm and artery dissection. Tofacitinib: dose-dependant risk of venous thromboembolic events. Ondansetron in the first trimester of pregnancy : a highly debated risk of orofacial cleft defects. Fingolimod : contraindicated during pregnancy due to suspected risk of congenital malformations. Ranitidine: global market withdrawal due to contamination with nitrosamines. Ulipristal for uterine fibroids : market withdrawal due to risk of severe liver injury. Ingenol mebutate : market withdrawal due to paradoxical risk of skin cancers.

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en